Researchers Stephan, Cummings and Fitzgerald introduced a drinkable gene‑therapy foam formulation designed to coat the esophageal lumen and deliver genetic payloads to constrictive esophageal carcinoma sites. The delivery method aims to overcome access limitations for local gene transfer and reduce systemic exposure by providing mucosal adherence and prolonged contact time. Preclinical results reported localized transduction and tolerability in animal models. Key next steps are GMP-compatible formulation development, biodistribution and mucosal safety studies, and early clinical feasibility trials for focal esophageal malignancies or precancerous lesions.